Lytix Biopharma’s innovative and unique solution emphasized in national clinical research report

Hear our CEO, Øystein Rekdal, explaining how our technology has the potential to solve the major challenge in current cancer therapy

"Norwegian cancer medicine is attracting attention", read article in TV2 news

First patient dosed in Part 2 of Verrica Pharmaceuticals' Phase II study evaluating LTX-315

Lytix Biopharma appoints Karsten Bruins Slot as Director Clinical Development